Global High-Priority Regulatory Events — June 09, 2026

09-06-2026

Anupam Rasayan India Limited has launched a mandatory open offer under SEBI SAST Regulations to acquire up to 26% of Bliss GVS Pharma Ltd at ₹299 per share, implying a maximum payout of approximately ₹829.8 Crore for 2.77 Crore equity shares. The offer opens on July 16, 2026 and closes on July 29, 2026; acceptance will be on a proportionate basis if oversubscribed, and no competing offer exists as of the Draft Letter of Offer date.

• · The offer is unconditional (not subject to minimum acceptance).
• · If oversubscribed, acceptance will be on a proportionate basis limited to 26% of expanded voting share capital.
• · No competing offer exists as of the Draft Letter of Offer date (competition deadline: June 22, 2026).
• · Offer price can be revised upward before July 15, 2026 (last working day before the tendering period).
• · Non-resident shareholders (NRI, OCB, FPI) must submit relevant RBI or other regulatory approvals or risk rejection of their tendered shares.
• · The Acquirer may withdraw the offer under specific conditions; any withdrawal triggers a public announcement within two working days.

09-06-2026

Vindhya Telelinks Limited has published newspaper advertisements regarding the compulsory transfer of unpaid/unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF). The notices were published on June 9, 2026, in Financial Express (English) and Dainik Jagran (Hindi), and are also available on the company's website.

• · The company is transferring unpaid/unclaimed dividends and shares to IEPF as per regulatory requirements.
• · Notices published in Financial Express (English) and Dainik Jagran (Hindi) on June 9, 2026.
• · The notice is also available on the company's website at https://www.vtlrewa.com.

09-06-2026

MTNL received a financial disincentive order from TRAI dated June 8, 2026, for contravention of Quality of Service regulations for Broadband (Wireline) service for the quarter ending June 2025, with a penalty of ₹6,00,000 (Rupees Six Lakhs). The company states there is no material impact on its financial, operational, or other activities.

• · The penalty is for contravention of Standards of Quality of Service of Access (Wireline and Wireless) and Broadband (Wireline and Wireless) Service Regulations, 2024 (06 of 2024).
• · The order was received on June 8, 2026, and disclosed on June 9, 2026.
• · The company explicitly states that there is no material impact on financial, operation, or other activities beyond the penalty amount.

09-06-2026

Ircon International Limited has published a public notice in Financial Express (English) and Jansatta (Hindi) on June 9, 2026, regarding the transfer of unpaid dividends and equity shares to the Investor Education and Protection Fund (IEPF) Authority. This is a routine regulatory compliance filing under SEBI Listing Regulations and does not contain any financial performance data or material business updates.

• · The public notice was published in Financial Express (All Edition, English) and Jansatta (Delhi Edition, Hindi) on June 9, 2026.
• · The notice pertains to transfer of unpaid dividends and equity shares to the IEPF Authority.
• · The filing is made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

09-06-2026

Avi Polymers Ltd. informed shareholders that the temporary suspension of trading in its shares by BSE was due to a misunderstanding during a physical verification visit, where officials were mistakenly directed to an unrelated office in the same building. The company has provided comprehensive evidence to BSE, and the process for revocation of the suspension is underway. The company reassures that operations and compliance remain unaffected.

• · The suspension was triggered by an adverse observation from BSE after officials inspected a different premises with similar office/gala numbers.
• · The company provided supporting evidence including proof of registered office address, photographs, videos, and other records.
• · BSE has acknowledged the representations and the rectification process is underway.
• · The company's registered office address is S-203 Shreejala Prime, Near Priyan Heritage, Opp Prajapita, Bha a Vidh a, Sardar j, Ana ujara.

09-06-2026

Emkay Global Financial Services Limited received in-principle approvals from NSE and BSE on June 8, 2026, for listing a total of 793,400 equity shares of ₹10 each, allotted upon conversion of warrants issued on a preferential basis. The shares are being issued to promoters Krishna Kumar Karwa (693,400 shares) and Prakash Kacholia (100,000 shares). The listing is subject to confirmation from depositories NSDL/CDSL for credit to beneficiaries' accounts.

• · The in-principle approvals were granted via NSE letters NSE/LIST/55288 and NSE/LIST/55492, and BSE letters LOD/PREF/AP/FIP/337/2026-27 and LOD/PREF/SS/FIP/342/2026-27.
• · The shares have distinctive numbers ranging from 26715032 to 27130131.
• · Listing will be effective only after confirmation from depositories (NSDL/CDSL) of credit to beneficiaries' accounts.

09-06-2026

Reliance Communications Limited has informed stock exchanges about the 72nd meeting of the Committee of Creditors (CoC) scheduled for June 09, 2026, as part of the ongoing corporate insolvency resolution process under the Insolvency and Bankruptcy Code, 2016. The company has been under the management of Resolution Professional Mr. Anish Niranjan Nanavaty since June 28, 2019, following an order by the NCLT Mumbai Bench.

• · The company has been under corporate insolvency resolution process since June 28, 2019.
• · The Resolution Professional is Mr. Anish Niranjan Nanavaty, appointed by NCLT Mumbai Bench.
• · The meeting is the 72nd meeting of the Committee of Creditors.

09-06-2026

Embassy Developments Limited (formerly Equinox India Developments Limited) received a disclosure from its promoter group, Embassy Property Developments Private Limited, regarding the release of a pledge over 2,00,00,000 (Two Crore) equity shares. The pledge release was executed on June 4, 2026, and intimated to the company on June 5, 2026, with the company notifying the exchanges on June 9, 2026. Post-release, the promoter group continues to hold the same number of shares (19,37,92,592) as before the transaction, with no change in ownership.

• · The pledge release was intimated under Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
• · The number of shares held by the promoter group remained unchanged at 19,37,92,592 (13.94%) both before and after the release of pledge.
• · The pledge release transaction was executed on June 4, 2026, and intimation was sent on June 5, 2026.
• · The transaction was off-market (pledge release), not a buy/sell.

09-06-2026

Reliance Home Finance Limited (RHFL) is undergoing Corporate Insolvency Resolution Process (CIRP). The 10th meeting of the Committee of Creditors (CoC) was held on June 9, 2026, via video conferencing, as intimated by Resolution Professional Umesh B. Sonkar. No financial figures or outcomes from the meeting were disclosed in this filing.

• · The CIRP was initiated on September 20, 2025.
• · The 10th CoC meeting was held on June 9, 2026, at 3:00 PM IST via video conferencing.
• · The company's BSE scrip code is 540709, NSE symbol is RHFL, and ISIN is INE217K01011.
• · Resolution Professional Umesh B. Sonkar is registered with IBBI (Reg. No: IBBI/IPA-001/IP-P-02619/2021-2022/14043).

09-06-2026

Inflection Point Acquisition Corp. III entered into Amendment No. 2 to its Business Combination Agreement with Air Water Ventures Holdings Limited, reducing the aggregate base consideration from $300,000,000 to $200,000,000 and lowering the maximum earnout shares from 30,000,000 to 20,000,000. The amendment also modifies earnout triggers, including revenue and EBITDA run-rate targets through June 2028. No other changes were made to the agreement.

• · The BCA Amendment was entered into on June 5, 2026.
• · Triggering Event I requires annual revenue run rate ≥ $80M by December 31, 2027.
• · Triggering Event II requires annual EBITDA run rate ≥ $30M by December 31, 2027.
• · Triggering Event III requires both annual revenue run rate ≥ $160M and annual EBITDA run rate ≥ $70M by June 30, 2028.
• · Triggering Event IV requires PubCo's share price ≥ $20.00 for 30 of 45 consecutive trading days between six months post-closing and June 30, 2028.
• · The earnout shares are now split into four equal tranches of 5,000,000 ordinary shares each.
• · An updated investor presentation was furnished as Exhibit 99.1.

09-06-2026

Pharmaceutical Resource Technology, Inc. filed Amendment No. 4 to its S-1 registration statement for an IPO of up to 100,000,000 shares of common stock at $0.50 per share, with a concurrent resale offering of up to 170,175,496 shares by selling stockholders. The company operates in honey straw manufacturing, pharmaceutical/dietary supplements, and building/construction services in Singapore, with 66% of revenue from construction. However, the offering is self-underwritten on a best-efforts basis with no minimum purchase requirement, meaning the company may raise substantially less than the maximum $49.9 million, and investors face significant dilution and a high risk of total loss.

• · The company is a Wyoming corporation with principal executive offices in Singapore and does not legally own any subsidiaries.
• · Operations are heavily dependent on a related-party relationship with Superbee Network Singapore Pte. Ltd., which provides personnel and operational support; the two executive officers/directors also control Superbee.
• · The offering will terminate upon sale of all shares or 365 days after the effective date (extendable by 90 days by the Board).
• · There is no public market for the stock; the company intends to apply for OTCQB quotation but has no arrangement with any market maker.
• · The offering price of $0.50 per share was arbitrarily determined by management and bears no relationship to assets, earnings, or book value.
• · The company has only two permanent employees (the executive officers/directors).
• · The resale offering by selling stockholders is separate; the company will not receive any proceeds from those sales.
• · Transactions may be subject to penny stock rules, imposing additional broker-dealer obligations.

09-06-2026

Novanta Inc. announced a definitive agreement to acquire Riverpoint Medical for $1.2 billion upfront plus a $250 million milestone payment in Q1 2027, expected to close in Q3 2026. The acquisition is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows, and is projected to double recurring medical consumables revenue to approximately $300 million. However, the upfront purchase price of $1.2 billion represents approximately 19x Riverpoint's estimated 2026 Adjusted EBITDA excluding synergies, indicating a high valuation multiple, and the transaction will increase Novanta's net leverage ratio to approximately 2.7x post-closing.

• · Riverpoint Medical will be reported under Novanta's Medical Solutions operating segment.
• · Novanta expects net leverage ratio of approximately 2.7x after closing, reducing to below 2.3x by year-end 2027.
• · Transaction financed through cash on hand, existing credit facility, and a $300 million equity raise.
• · Novanta confirms its previously issued Q2 and Full Year 2026 financial guidance for the standalone company and will update guidance post-close.
• · Conference call scheduled for June 9, 2026 at 8:30 a.m. ET.
• · Riverpoint has manufacturing operations in Portland, Oregon and San Jose, Costa Rica.

09-06-2026

Inflection Point Acquisition Corp. VI (IPFX) filed a Form 425 with the SEC on June 9, 2026, in connection with its proposed business combination with Quantum Space, LLC. The filing includes social media communications from Quantum Space and its executives (Kam Ghaffarian, Jim Bridenstine, Kerry Wisnosky) promoting the merger, but contains no financial data or performance metrics. The filing is primarily a regulatory disclosure with extensive forward-looking statements and risk factors, highlighting that Quantum Space's flagship vehicle, Ranger, is still in development and has not been manufactured, operated, or sold to date.

• · Quantum Space's flagship vehicle, Ranger, is currently in development and has not been manufactured, operated, or sold to date.
• · Ranger is intended to have a refuelable and modular architecture with an operational life of up to 15 years.
• · The business combination requires shareholder approval and is subject to various closing conditions.
• · Inflection Point's final prospectus for its IPO was filed with the SEC on March 30, 2026 (File No. 333-292443).
• · The filing includes social media posts from Quantum Space and its executives on LinkedIn and X (formerly Twitter) dated June 8, 2026.

09-06-2026

On June 4, 2026, Qorvo's Compensation Committee approved FY2027 performance-based restricted stock unit (PBRSU) awards for named executive officers, with 50% tied to non-GAAP operating income, 25% to gross margin, and 25% to revenue objectives. The committee also granted a retention award to Philip J. Chesley comprising 9,618 service-based RSUs and 9,618 PBRSUs linked to organic HPA revenue growth. The awards reflect shareholder feedback from the 2025 say-on-pay vote, removing prior objectives-based metrics. The fair market value per share was set at $103.97.

• · The FY2027 PBRSUs use three performance metrics: non-GAAP operating income (50% weight), gross margin (25%), and revenue (25%).
• · The non-GAAP operating income and gross margin objectives are measured over three one-year periods (FY2027, FY2028, FY2029); the revenue objective is measured over a single one-year period (FY2029).
• · Each officer can earn up to 200% of target PBRSUs for each metric if objectives are fully met.
• · The Retention Award for Mr. Chesley includes 9,618 service-based RSUs vesting in two equal annual installments and 9,618 PBRSUs tied to organic HPA revenue growth over FY2027 and FY2028.
• · The Retention Award PBRSUs have a maximum payout of 100% of target (not 200%).
• · The Retention Award RSUs (but not PBRSUs) will fully vest upon a qualifying termination in connection with a change in control.
• · Upon the closing of the merger with Skyworks, the Retention Award PBRSUs will remain in place and eligible to be earned post-closing, not measured at closing.
• · The fair market value per share for both awards was $103.97, based on the June 4, 2026 closing price.
• · The awards were approved in response to shareholder feedback from the 2025 say-on-pay vote, removing prior objectives-based metrics.

09-06-2026

FutureCorp Space Acquisition 1, a blank check company focused on the global space economy, announced the pricing of its $200,000,000 initial public offering of 20,000,000 units at $10.00 per unit. The units are expected to begin trading on the NYSE on June 5, 2026, under the ticker 'FTRAU', with the offering closing on June 8, 2026. The company has granted underwriters a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments.

• · The company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
• · The company's primary focus will be on companies in the global space economy and adjacent industries, including space manufacturing and component supply chains, launch platforms, in-orbit services and habitats, in-orbit computing and manufacturing, space-based telecommunications and Earth observation, and defense-related activities.
• · The registration statement relating to the securities became effective on June 4, 2026.
• · The units are expected to be listed on NYSE under the ticker symbol 'FTRAU'.
• · Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on NYSE under the symbols 'FTRA' and 'FTRAW', respectively.
• · An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering.
• · No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

09-06-2026

Cantor Equity Partners VII, Inc. filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 25,000,000 Class A ordinary shares at $10.00 per share, aiming to raise $250,000,000. The blank check company has not yet selected a business combination target and must complete an initial business combination within 24 months of the offering closing or liquidate. The sponsor purchased 7,187,500 founder shares for $25,000 (approximately $0.003 per share), resulting in immediate and substantial dilution for public shareholders, and has agreed to a private placement of 600,000 Class A shares at $10.00 per share ($6,000,000 aggregate).

• · The company is a blank check company (SPAC) incorporated in the Cayman Islands with SIC code 6770.
• · The underwriters have a 45-day option to purchase up to an additional 3,750,000 Class A ordinary shares to cover over-allotments.
• · Unlike some other SPAC IPOs, this offering does not include warrants for investors.
• · The sponsor note of up to $4,312,500 will not bear interest and is convertible into Class A shares at $10.00 per share no earlier than 60 days after the offering date.
• · If the company fails to complete a business combination within 24 months, it will redeem 100% of public shares from the trust account.
• · Public shareholders have redemption rights upon completion of a business combination, but those holding more than 15% of public shares may be restricted from redeeming without prior consent if a shareholder vote is held.
• · The founder shares (Class B) automatically convert into non-redeemable Class A shares upon consummation of the initial business combination.
• · The company has not initiated any discussions with any business combination target.

09-06-2026

Brilliant N.E.V. Corp. filed an 8-K on June 9, 2026, covering Items 5.01 (Change in Control), 5.02 (Departure of Directors or Principal Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing indicates significant corporate governance changes, including a change in control and officer/director departures, but no specific financial figures or period-over-period comparisons were provided in the filing metadata.

• · The company was formerly known as Clancy Corp (filings through 2023-08-09).
• · The company's SIC code is 2840 (Soap, Detergent, Cleaning Preparations, Perfumes, Cosmetics).
• · Fiscal year ends July 31.
• · The filing includes items related to changes in control, officer/director changes, and amendments to governing documents.

09-06-2026

Uranium Energy Corp (UEC) reported a net loss of $52.3M for Q3 FY2026 (three months ended April 30, 2026), widening from a $30.2M loss in the same quarter last year, driven by higher operating costs and a $19.4M fair value loss on equity securities. For the nine-month period, net loss was $76.6M vs $60.6M a year ago. The company significantly strengthened its balance sheet, raising $508.2M in net proceeds from share issuances, boosting cash to $488.1M from $148.9M at July 31, 2025, while total assets grew to $1.54B. However, sales were nil in Q3 (vs $20.2M in the prior nine months) and operating cash flow burned $90.1M year-to-date.

• · No sales were recorded in Q3 FY2026 (vs nil in Q3 FY2025), while nine-month sales dropped 69.8% to $20.2M from $66.8M.
• · Mineral property expenditures surged 88.4% YoY in Q3 to $29.5M, driven by a 143% increase in development costs ($15.8M vs $6.5M) and a 148% increase in exploration costs ($7.6M vs $3.1M).
• · Fair value loss on equity securities was $19.4M in Q3 FY2026, compared to a $4.3M loss in Q3 FY2025.
• · Interest income rose to $4.2M in Q3 FY2026 from $0.6M in Q3 FY2025, reflecting higher cash balances.
• · Cash used in operating activities more than doubled to $90.1M for the nine months (vs $41.0M).
• · Net cash provided by financing activities was $505.1M, primarily from share issuances ($508.2M).
• · Inventories increased 9.1% to $86.5M, driven by a 635% increase in uranium concentrates from extraction ($8.4M vs $1.1M).
• · Equity-accounted investments rose to $63.8M from $55.8M, and investment in equity securities increased to $65.9M from $28.5M.
• · Total liabilities decreased 5.8% to $116.6M from $123.8M.
• · Weighted average diluted shares outstanding increased 14.1% to 490.7M in Q3 FY2026 from 429.9M in Q3 FY2025.

09-06-2026

AITX filed its 10-K for the fiscal year ended February 28, 2026, reporting a 26% increase in revenue to $7.7M, driven by a 37% surge in device rental activities to $6.9M. However, direct sales of goods and services declined 24% to $825K, and the company continued to operate at a net loss of $14.5M, though this was a 23% improvement from the prior year's $18.9M loss. The company also engaged in extensive debt-for-equity exchanges and share issuances, with outstanding shares rising from 9.2B to 14.4B over the two-year period, and then dropping sharply to 267.9M by February 28, 2026, reflecting a reverse stock split or similar restructuring.

• · The company's authorized dealer network has grown to over 100 dealers across the United States, Canada, and the European Union.
• · Enterprise and Fortune 500 end users serve as both a revenue base and credibility base for SARA adoption.
• · Shares outstanding dropped dramatically from 14,412,453,768 on Feb 28, 2025 to 267,872,804 on Feb 28, 2026, indicating a likely reverse stock split.
• · During the period March 1, 2025 to February 28, 2026, the company issued 50,403,802 shares through other registered sales.
• · The company recorded a loss on disposal of fixed assets of $22,312 in FY 2026, compared to $0 in the prior year.
• · Operating lease cost and rent increased 5% YoY to $251,883.

09-06-2026

Ribbon Acquisition Corp. deposited $125,000 into its trust account to extend the deadline for completing its initial business combination by one month, from May 15, 2026 to June 15, 2026. This is the company's second extension payment, indicating continued but time-pressured progress toward a merger target.

• · The extension moves the deadline from May 15, 2026 to June 15, 2026.
• · The filing was signed on June 8, 2026, and filed on June 9, 2026.
• · Ribbon Acquisition Corp. is a blank check company (SPAC) incorporated in the Cayman Islands, headquartered in Tokyo, Japan.
• · The company's securities (Class A ordinary shares, units, and rights) are listed on Nasdaq under symbols RIBB, RIBBU, and RIBBR respectively.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

09-06-2026

Starton Holdings, Inc. filed Amendment No. 4 to its S-1 registration statement for an initial public offering of 5,000,000 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company is a clinical-stage biotechnology firm focused on improving cancer therapies via proprietary delivery technology. The offering includes a 45-day underwriter option for an additional 750,000 shares, and the company has applied to list on Nasdaq under the symbol 'STA'.

• · The company is a clinical-stage biotechnology company focused on improving standard-of-care therapies for cancer through proprietary delivery technology systems.
• · The company has applied to list its common stock on the Nasdaq Capital Market under the symbol 'STA'.
• · The estimated initial public offering price per share is between $5.00 and $7.00.
• · The underwriters have a 45-day option to purchase up to an additional 750,000 shares to cover over-allotments.
• · The company is an 'emerging growth company' and a 'smaller reporting company' under federal securities laws.
• · The company's principal executive offices are located at 215 College Road, Suite 300, Paramus, NJ 07652.

09-06-2026

For the three months ended March 31, 2026, AIBOTICS, INC. reported net loss of $418,105, an improvement from the $591,397 loss in the same period of 2025, driven primarily by reduced general and administrative expenses ($359,463 vs $531,647). However, revenue dropped to $0 from $2,183 in the prior year, and the company's accumulated deficit widened to $13.44M. Cash used in operating activities increased to $36,258 from $28,360 in the prior year period, while cash and total assets declined modestly.

• · Net cash used in operating activities increased to $36,258 in Q1 2026 from $28,360 in Q1 2025.
• · Interest expense decreased slightly to $58,642 in Q1 2026 from $61,933 in Q1 2025.
• · Cash provided by financing activities was $69,176 in Q1 2026 (proceeds from convertible note payable $98,000, partially offset by repayments of $28,824), compared to $0 in Q1 2025.
• · Total liabilities increased to $5,051,334 as of March 31, 2026, from $4,834,905 as of December 31, 2025.
• · Amortization expense for intangible assets was $169,956 in Q1 2026, up from $164,234 in Q1 2025.
• · Common shares outstanding more than doubled from 45.2M (Mar 31, 2025) to 539.4M (Mar 31, 2026).

09-06-2026

Duos Technologies Group, Inc. announced that effective June 8, 2026, Leah Brown stepped down as Chief Financial Officer to resume her previous role as Senior Vice President of Accounting, and Adrian Goldfarb was appointed Interim Chief Financial Officer. Mr. Goldfarb, who previously served as CFO from April 2024 to November 2025 and from 2015 to 2022, will lead a search committee to hire a permanent CFO, with a replacement expected within 60 to 90 days. The filing does not disclose any financial results or performance metrics, so no positive or negative financial trends are reported.

• · Adrian Goldfarb has been serving as Strategic Advisor to the CEO since November 2025 and as President of Duos Technologies, Inc. since March 2026, overseeing the rail industry subsidiary's operations and planned divestment.
• · Mr. Goldfarb previously served as CFO from April 2024 to November 2025 and from 2015 to 2022, and as a Director from April 2010 to November 2020.
• · He managed the Company's listing on the Nasdaq Capital Market in 2020.
• · Mr. Goldfarb currently serves as non-Executive Chairman of GelStat Corporation.
• · Prior to Duos, he served as CFO for Ecosphere Technologies, overseeing growth from $0 to $24 million and profitability.

09-06-2026

Lionheart Holdings appointed Freddy J. Martinez (age 70) as a Class III director effective June 6, 2026, filling a new board vacancy. The appointment reflects the Company's strategic shift to focus on oil and gas opportunities in Venezuela. Mr. Martinez brings over 40 years of investment management and energy sector experience, with no cash compensation paid for his services.

• · Mr. Martinez is independent under NASDAQ rules and serves as President/CEO of Forem Investments LLC, a registered investment adviser founded in December 2013.
• · He holds an MBA in finance from Wharton, an M.S. in Engineering from the Moore School, and a B.S. in Mechanical Engineering from Universidad Simón Bolívar.
• · The Company's definitive proxy statement for an extension of time through March 20, 2027 was mailed to shareholders of record as of May 15, 2026; a special meeting is scheduled for June 15, 2026.
• · Mr. Martinez has not received any cash compensation; he entered into a standard director indemnification agreement and the Letter Agreement dated June 17, 2024.

09-06-2026

IQM Finland Oy and Real Asset Acquisition Corp. (RAAQ) announced that the SEC declared effective the Registration Statement on Form F-4 for their proposed business combination. The Extraordinary General Meeting of RAAQ shareholders to vote on the transaction is scheduled for June 25, 2026. The filing does not disclose any financial performance metrics, so no positive or negative trends can be reported.

• · The Registration Statement on Form F-4 was declared effective by the SEC on June 5, 2026.
• · RAAQ mailed the definitive proxy statement/prospectus to shareholders as of June 3, 2026, the record date for the Extraordinary General Meeting.
• · The Business Combination Agreement was entered into on February 22, 2026.
• · RAAQ's securities are listed on Nasdaq under symbols RAAQU, RAAQ, and RAAQW.
• · The filing includes forward-looking statements and risk factors related to the transaction and IQM's business.

09-06-2026

Real Asset Acquisition Corp. (RAAQ) and IQM Finland Oy announced that the SEC declared effective IQM's Registration Statement on Form F-4 for their proposed business combination, which will make IQM a publicly traded company. RAAQ has mailed the definitive proxy statement/prospectus to shareholders as of June 3, 2026, with an Extraordinary General Meeting to be held to vote on the transaction.

• · The Business Combination Agreement was entered into on February 22, 2026.
• · The Registration Statement was declared effective by the SEC on June 5, 2026.
• · Shareholders of record as of June 3, 2026 are entitled to vote at the Extraordinary General Meeting.
• · The combined company's securities (RAAQU, RAAQ, RAAQW) trade on The Nasdaq Stock Market LLC.
• · The exercise price for redeemable warrants is $11.50 per Class A ordinary share.

09-06-2026

Onconetix, Inc. filed an S-1 registration statement for a proposed securities offering. The company is a commercial-stage biotechnology firm focused on oncology, owning Proclarix, an in vitro diagnostic test for prostate cancer approved in the EU and being developed in the U.S. via a LabCorp agreement. However, the company has incurred net losses since inception, abandoned commercialization of its only other product (ENTADFI), and faces substantial doubt about its ability to continue as a going concern, with cash of only $3.7 million as of March 31, 2026, and an accumulated deficit of $135.4 million.

• · Proclarix is CE-marked and for sale in Europe; in the UK, ~100 tests were carried out in a screening initiative as of March 31, 2026.
• · Two peer-reviewed publications on Proclarix were published in Q1 2026: one in BMC Cancer (Schiess et al., 371 men) and one in Cancers (Athanasiou et al., 132 men).
• · Proteomedix initiated a multi-center PRIME study with LabCorp to evaluate Proclarix in the U.S., targeting up to 500 men; first participants enrolled.
• · The company abandoned commercialization of ENTADFI as of December 31, 2025, and terminated three employees involved with the program.
• · Onconetix has no internal manufacturing capabilities and relies on single-source third-party suppliers for Proclarix.
• · The company believes its current cash balance is not sufficient to fund operations for one year from the date of issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

09-06-2026

Aeon Acquisition I Corp. adopted a Second Amended and Restated Memorandum and Articles of Association on June 2, 2026, filed via an 8-K on June 9, 2026. The updated governing documents formalize the company's structure as a Cayman Islands exempted company limited by shares, with an authorized share capital of $50,000 divided into 450,000,000 Class A ordinary shares, 45,000,000 Class B ordinary shares, and 5,000,000 preference shares, all at $0.0001 par value. The company is designated as a special purpose acquisition company (SPAC) with a 12-month (extendable to 18-month) completion window to consummate a business combination valued at least 80% of trust assets, and it retains the power to register by continuation outside the Cayman Islands.

• · The company is incorporated in the Cayman Islands with registered office at Cassia Court, Suite 716, 10 Market Street, Camana Bay, Grand Cayman KY1-9006.
• · The financial year end is December 31.
• · The company has the power to register by continuation as a body corporate under the laws of any jurisdiction outside the Cayman Islands.
• · The business combination must involve a target business with an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding deferred underwriting commissions and taxes on interest income).
• · The company may not effectuate a business combination solely with another blank check company or similar company with nominal operations.
• · The Over-allotment Option allows underwriters to purchase up to an additional 15% of the units issued in the IPO at $10 per unit, less underwriting discounts and commissions.
• · The company is prohibited from issuing shares to bearer.

09-06-2026

Syschem (India) Ltd. has received an order dated June 6, 2026 from the Judicial Magistrate 1st Class, Chandigarh, directing the recovery of ₹55,57,630.61 in favor of the company from accounts linked to a previously disclosed fraudulent transfer of funds. The company is implementing the order and will provide further material updates if necessary. No negative or flat metrics are present in this filing.

• · The order was passed on June 6, 2026 by Judicial Magistrate 1st Class, Chandigarh.
• · The company received the order on June 9, 2026.
• · The order pertains specifically to the fraudulent transfer of funds previously reported on April 15, 2026.
• · The recovery is from accounts identified during investigation of the fraudulent transactions.
• · The company is taking steps to implement the order and will disclose any material impact subsequently.

09-06-2026

NusaTrip Inc. announced multiple executive changes on June 2, 2026, including the appointment of Loïc Gautier as CFO (annual base salary $150,000), Binglin Yu as CTO (RMB 55,000/month), and Hongwei Zhang as Chief Revenue Officer (RMB 55,000/month, effective June 20). The company also removed COO Ade Irawan effective June 2, and entered into an employment agreement with CEO Patrick Soetanto Tjin (base salary $150,000/year plus minimum 25% performance bonus). Notably, the previously announced CFO appointment of Wallace Tzi Chun Foo did not proceed due to personal reasons.

• · CFO appointment of Wallace Tzi Chun Foo did not become effective due to personal and family reasons; no disagreement with the company.
• · New CFO Loïc Gautier has over 10 years of experience in technology, e-commerce, and corporate finance in Southeast Asia; founded Leflair, acquired by SOPA in 2021; helped SOPA with its Nasdaq IPO in 2022.
• · New CTO Binglin Yu holds a Bachelor of Science in Computer Science and Technology from Peking University.
• · New CRO Hongwei Zhang holds an MBA from Pennsylvania State University and is fluent in English and Mandarin.
• · Former COO Ade Irawan was removed from all officer, management, banking, administrative, platform access, and other authorized capacities with the company and its subsidiaries.
• · CEO Patrick Soetanto Tjin's employment agreement includes a minimum 25% performance bonus based on base salary.
• · CRO Hongwei Zhang previously worked at INTECH TRAVEL GROUP, a principal airline content supplier to NusaTrip, from November 2023 to September 2025.

09-06-2026

Brand Engagement Network Inc. (BEN) entered into a definitive agreement on June 8, 2026, to form INTERVENT Health AI, Inc., a 50/50 healthcare AI joint venture with INTERVENT International, LLC. The JV will develop AI-powered health coaching solutions combining BEN's conversational AI with INTERVENT's clinically validated methodologies and datasets. BEN, through its subsidiary SKYE AI USA, will receive 35% of certain JV revenues from North American commercialization under a five-year exclusive arrangement, while the JV will receive 50% of gross revenues from proposed non-exclusive international reseller deals in Latin America and Africa. No financial performance metrics or revenue projections were disclosed, and the agreement is subject to performance milestones.

• · The JV's Board of Directors will consist of one BEN-appointed director, one INTERVENT-appointed director, and one mutually agreed independent director.
• · The Shareholder Agreement includes customary governance, pre-emptive rights, and ownership protection provisions, including restrictions on issuances that would reduce either founding shareholder below specified ownership thresholds without approval.
• · BEN is an emerging growth company as defined under SEC rules.
• · The agreement is subject to performance milestones for the five-year exclusive North American arrangement.

09-06-2026

Parabilis Medicines, Inc. filed an S-1/A registration statement for an initial public offering of 33,333,334 shares of common stock at an assumed price of $18.00 per share, with an overallotment option for up to 5,000,000 additional shares. The company expects net proceeds of approximately $553.1 million from the offering (or $636.8 million if the overallotment is exercised in full), plus an additional $75.0 million from a concurrent private placement with Regeneron. However, the company is not yet profitable, with net losses increasing from $117.9 million in 2024 to $145.9 million in 2025, and a net loss of $45.3 million for the three months ended March 31, 2026, compared to $38.3 million in the same period of 2025.

• · The company has granted the underwriters a 30-day overallotment option to purchase up to 5,000,000 additional shares.
• · Regeneron has agreed to purchase approximately $75.0 million in shares at 90% of the IPO price in a concurrent private placement, contingent on the IPO closing.
• · Pro forma as adjusted cash and cash equivalents after the offering and private placement would be approximately $957.1 million.
• · The company had an accumulated deficit of $586.8 million as of March 31, 2026.
• · Pro forma net loss per share (basic and diluted) for the year ended December 31, 2025 was $(1.81), and for the three months ended March 31, 2026 was $(0.56).
• · The company's convertible preferred stock balance of $814.5 million will convert to common and non-voting common stock upon the closing of the offering.
• · Interest income decreased 47.2% from $6.4 million in 2024 to $3.4 million in 2025, but increased 93.2% from $1.3 million in Q1 2025 to $2.4 million in Q1 2026.
• · Sublease income from a related party was $4.2 million in both 2024 and 2025, but was $0 in Q1 2026 compared to $1.1 million in Q1 2025.
• · The company effected a 1-for-1.5389 reverse stock split on June 3, 2026.
• · The proposed Nasdaq Global Market trading symbol is 'PBLS'.

09-06-2026

GSK plc announced a definitive agreement to acquire Nuvalent, Inc. for $10.6 billion ($124 per share in cash), representing a 40% premium to the last closing price. The deal includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer currently under FDA review with target decision dates in September and November 2026, plus a phase I HER2 inhibitor (NVL-330). The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, but will cause low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028.

• · The transaction is expected to close in Q3 2026, subject to tender of a majority of Nuvalent's Class A shares and HSR Act clearance.
• · GSK will assume Nuvalent's existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
• · The acquisition will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating.
• · GSK reaffirmed its 2026 dividend of 70p and progressive dividend policy.
• · GSK's FY 2026 guidance of 7-9% core operating profit and core EPS growth remains unchanged.
• · GSK expects low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028 from the transaction.
• · The acquisition is expected to be accretive to core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation.
• · Zidesamtinib has a target FDA decision date of 18 September 2026; neladalkib has a target decision date of 27 November 2026.
• · Both zidesamtinib and neladalkib have received FDA Breakthrough Therapy and Orphan Drug Designations.
• · The deal includes Nuvalent's preclinical portfolio of multiple programmes.

09-06-2026

NATHANS FAMOUS, INC. filed its 10-K annual report for fiscal year 2026, showing a decline in total revenue to $3.443M from $3.864M in fiscal 2025, a decrease of 10.9%. Net income also fell to $20.020M from $24.026M, down 16.7%, while Adjusted EBITDA decreased to $36.314M from $39.206M, a drop of 7.4%. The company continues to operate 65 franchised locations in 11 foreign countries and maintains licensing and branded product programs.

• · Interest expense decreased to $2.857M in fiscal 2026 from $4.106M in fiscal 2025.
• · Provision for income taxes was $8.170M in fiscal 2026, down from $8.735M in fiscal 2025.
• · Depreciation and amortization was $925,000 in fiscal 2026, compared to $957,000 in fiscal 2025.
• · Loss on debt extinguishment was $0 in fiscal 2026 versus $389,000 in fiscal 2025.
• · Share-based compensation increased to $1.132M in fiscal 2026 from $993,000 in fiscal 2025.
• · Transaction costs of $3.210M were incurred in fiscal 2026, with none in fiscal 2025.
• · Net cash used in investing activities was $370,000 in fiscal 2026, up from $225,000 in fiscal 2025.
• · Net cash used in financing activities was $21.262M in fiscal 2026, compared to $18.240M in fiscal 2025.
• · The company's packaged hot dogs are sold in all 50 states through major retailers including Walmart, Kroger, and Costco.
• · Franchisees operated 65 locations in 11 foreign countries as of March 29, 2026.

09-06-2026

22nd Century Group, Inc. filed an 8-K announcing stockholder approval of a 1-for-20 reverse stock split, effective at 12:01 a.m. on June 12, 2026. The reverse split reduces the number of issued and outstanding shares of common stock without adjusting par value or reducing authorized shares. Fractional shares will be rounded up to the nearest whole share.

• · Reverse stock split effective date: June 12, 2026 at 12:01 a.m.
• · Par value remains $0.00001 per share; authorized shares unchanged.
• · Fractional shares resulting from the split will be rounded up to the nearest whole share.
• · Old certificates will represent the post-split number of whole shares until surrendered.

09-06-2026

Cocrystal Pharma, Inc. appointed James Sapirstein as CEO effective June 3, 2026, replacing co-CEOs Sam Lee and James Martin. Mr. Sapirstein receives a $265,000 base salary, a 50% performance bonus, and an initial grant of 235,000 stock options at $1.05 per share, with a potential additional grant of 235,000 options after six months. Sam Lee remains President and Chief Scientific Officer, and James Martin continues as CFO.

• · James Sapirstein previously served as CEO of Entero Therapeutics from October 2019 to February 2025 and as a consultant from February 2025 to March 2026.
• · The initial option grant vests in four equal annual installments beginning June 3, 2027, with full acceleration upon a Change in Control and 50% acceleration upon termination without Cause.
• · The potential additional option grant is subject to continued employment, performance targets, and Compensation Committee approval, with an exercise price equal to the closing price on the grant date.

09-06-2026

Onward Technologies Limited has completed a buyback of up to 5,48,780 equity shares through a tender offer route. The post-buyback public advertisement was published on June 9, 2026, in Financial Express (English), Jansatta (Hindi), and Navshakti (Marathi). The buyback was conducted in accordance with SEBI regulations.

• · The buyback was conducted via a tender offer route on a proportionate basis.
• · The post-buyback public advertisement was published on June 9, 2026, in Financial Express (English), Jansatta (Hindi), and Navshakti (Marathi).
• · The company's registered office is at 2nd floor, Sterling Centre, Dr. A.B. Road, Worli, Mumbai 400018.

09-06-2026

Aspect Global Ventures Private Limited has launched an open offer to acquire up to 26,98,298 fully paid-up equity shares (26% of voting share capital) of Iykot Hitech Toolroom Limited at ₹8.50 per share, aggregating ₹2,29,35,533. The offer follows the forfeiture of 99,01,931 partly paid-up shares (approved by the board on January 9, 2026, and confirmed by BSE on May 11, 2026), reducing the voting share capital to 1,03,78,069 fully paid-up shares. The board of the target company was reconstituted on April 27, 2026, with two erstwhile directors resigning and three new additional directors appointed, though the corporate action for forfeiture is still under process.

• · The offer price of ₹8.50 per share has not been revised since the initial public announcement.
• · The Committee of Independent Directors of the target company has recommended that the offer is fair and reasonable and in line with SEBI (SAST) Regulations.
• · The target company's equity shares are listed only on BSE (Scrip Code: 522245, ISIN: INE079L01013) and are not suspended from trading.
• · No regulatory actions, administrative warnings, or proceedings are pending against the acquirer, its promoters, or the target company as of the date of the Letter of Offer.
• · The corporate action for forfeiture of the 99,01,931 partly paid-up shares is still under process as of the date of the Letter of Offer.
• · The erstwhile target company directors (Likhitta Dugar and Annjana Dugar) resigned on April 27, 2026, and three new additional directors were appointed on the same date, subject to shareholder approval.

09-06-2026

Soluna Holdings reported Q1 2026 revenue up 58% YoY, with Bitcoin hosting revenue up 178% YoY and a record hash rate, marking the fourth consecutive quarter of growth. However, the company also disclosed ongoing construction and development risks, including transformer repairs at Project Dorothy 1A that were completed in May, and noted that Project Kati 1B construction is still ongoing with Phase 3 ahead of schedule. The company regained Nasdaq compliance and signed a definitive JV agreement for Kati 2, but tenant due diligence and commercial negotiations remain in early stages.

• · Soluna regained compliance with Nasdaq listing requirements.
• · A definitive joint venture agreement was signed with Metrobloks for Kati 2, replacing the prior non-binding MOU.
• · A definitive purchase agreement was signed for 300 acres for Dorothy 3.
• · Briscoe Wind Farm (150 MW) was successfully integrated into operations.
• · Project Kati 1B Phase 1 (12 MW) achieved substantial completion; Phase 2 (9 MW) achieved mechanical and power commissioning; Phase 3 (14 MW) is ahead of schedule.
• · Project Annie (74 MW) is being developed for a potential new customer; ERCOT interconnection studies are nearing completion.
• · Tenant due diligence continues with Hyperscalers and Neoclouds; formal commercial negotiations started with at least one potential tenant for Kati 2.
• · The company engaged a top-tier investment bank to lead capital raising for Kati 2.
• · Transformer repair work at D1A was completed in May, returning operations to full capacity.

09-06-2026

Lisata Therapeutics entered into an amendment and waiver to its merger agreement with Kuva Labs, extending the offer commencement deadline and outside date, and receiving delayed interim operating payments totaling $250,000. The amendment also adds a representation by Parent regarding financial ability to fund the merger, including a non-binding indication of interest for up to $25 million in convertible notes. However, the lack of committed financing and the extension of deadlines introduce uncertainty about the merger's completion.

• · The original merger agreement was dated March 6, 2026.
• · The offer commencement deadline was extended from 60 business days after March 6 to 65 business days.
• · The outside date was extended from July 6, 2026 to July 17, 2026, with a possible further extension to August 17, 2026 upon payment of a $1.5 million extension fee.
• · Parent and Purchaser represent they have a reasonable, good faith belief that anticipated funding sources will be sufficient, but acknowledge no binding commitments exist.
• · The waiver includes a covenant not to sue during the waiver period (June 8 to June 10, 2026) and conditional waivers of claims related to delayed offer commencement and missed interim operating payment.
• · If Parent fails to make interim payments or commits a material breach, the Company may terminate Sections 2, 3, and 4 of the waiver.

09-06-2026

PRI CAF Private Limited, a promoter group entity of Paisalo Digital Limited, reported the release of pledged shares on June 9, 2026, involving multiple promoter entities including Sunil Purushottanm Agarwal, Santanu Agarwal, Pro Fitcch Pvt. Ltd., PRI CAF Pvt. Ltd., and Equilibrated Venture Cflow Pvt. Ltd. The release of pledge was primarily for collateral for loans taken from IIFL Finance Ltd. Post-event, the total promoter shareholding in the company remains unchanged, with encumbered shares as a percentage of promoter shareholding at 23.11%.

• · The release of pledge involved 18,10,000 shares (0.20% of total share capital) for PRI CAF Private Limited.
• · Post-event, PRI CAF Private Limited's encumbered shares reduced from 90,36,000 to 72,26,000 shares (0.79% of total share capital).
• · Equilibrated Venture Cflow Pvt. Ltd. released 49,09,002 shares (0.54% of total share capital) from pledge, reducing its encumbered shares to 7,17,06,000 (7.88% of total share capital).
• · Sunil Purushottanm Agarwal's encumbered shares remained unchanged at 95,81,000 (1.05% of total share capital) with no event reported for him.
• · Santanu Agarwal's encumbered shares remained unchanged at 96,02,000 (1.06% of total share capital) with no event reported for him.
• · The ratio of security cover to amount involved for all pledge events (Encumbrance 2 to 7) ranged between 1.58 and 1.67.
• · All pledges were created solely for availing margin trading facility and do not involve any transfer of ownership or control of shares.

09-06-2026

Vas Infrastructure Ltd has informed the stock exchange that the 25th meeting of its Committee of Creditors (CoC) will be held on June 11, 2026, as part of the ongoing Corporate Insolvency Resolution Process (CIRP). The notice was filed by Resolution Professional Ashok Kumar Golechha under SEBI LODR regulations. No financial figures or performance comparisons are provided in this filing.

• · The company is under Corporate Insolvency Resolution Process (CIRP).
• · Resolution Professional's IBBI registration number: IBBI/IPA-002/IP-N000932/2019-20/12973.
• · AFA (Authorisation for Assignment) valid until December 31, 2026.

09-06-2026

Aspira Women's Health Inc. entered into securities purchase agreements on June 5, 2026, for a private placement generating gross proceeds of approximately $1.485 million. The offering includes 3.3 million shares of common stock and warrants to purchase up to 4.455 million shares at an exercise price of $0.75 per share. Net proceeds will be used for working capital and general corporate purposes.

• · The common warrants are exercisable immediately upon issuance and have a term of three years.
• · The purchase agreement includes customary representations and warranties, conditions to closing, termination provisions, and an anti-dilutive provision.
• · The company granted purchasers customary registration rights for the shares and shares underlying the warrants.
• · The private placement was conducted with accredited and institutional investors.

09-06-2026

Kanco Tea & Industries Limited has informed shareholders about the IEPF Authority's 'Saksham Niveshak' Second 100 Days Campaign (April 1, 2026 to July 9, 2026) to prevent transfer of shares to IEPF due to unclaimed dividends. The company is urging shareholders to update KYC details and claim unpaid dividends, noting that shares will be transferred to IEPF if dividends remain unclaimed for 7 consecutive years. No financial figures or period-over-period comparisons are provided in this filing.

• · The campaign runs from April 1, 2026 to July 9, 2026.
• · Shareholders holding shares in dematerialized mode must update KYC with their Depository Participants (DPs).
• · Shareholders holding physical shares must furnish PAN, contact details, bank account details, specimen signature, email ID, and nomination choice using forms ISR-1, ISR-2, ISR-3, ISR-4, SH-13, SH-14.
• · Unclaimed dividends will be paid via electronic mode only after KYC details are furnished.
• · If dividends remain unpaid/unclaimed for 7 consecutive years, equity shares will be transferred to IEPF, and reclaiming them requires filing e-Form IEPF-5, described as a 'long drawn and complex process'.

09-06-2026

PropShare Titania, the second scheme of Property Share Investment Trust (India's first SM REIT), reported strong performance for FY2025-26 with 100% occupancy throughout the year, a net distributable cash flow of ₹279.88 million, distribution per unit of ₹62,728.77, and an annualised yield of 9.00%. The scheme's Net Asset Value stood at ₹4,802.68 million (₹10,76,351.41 per unit). The asset, a LEED Platinum (O&M) certified Grade A+ office building in Thane (MMR), is fully leased to Fortune 500 and blue-chip tenants including Aditya Birla Capital, Concentrix, IQVIA, and Hitachi. The Investment Manager (PropShare Investment Manager Pvt Ltd) has invested 5% of the scheme's total units (₹23.74 crore) at listing, aligning interests with unitholders. The first Annual Meeting of Unitholders is scheduled for July 6, 2026.

• · The asset is LEED Platinum (O&M) certified and holds WELL Health-Safety Rating and BEE Five-Star certification.
• · The building has a total leasable area of 867,969 sq ft across a single tower; PropShare Titania encompasses 437,973 sq ft across six floors.
• · The Investment Manager's holding company has managed investments exceeding ₹2,600 crore.
• · The scheme's exit strategy includes sale of the property, sale of the SPV, or other opportunities subject to unitholder approval.
• · Thane MMR has seen consistent market rent growth of 4.8% CAGR since 2022 till December 2024, with a projected 5-year CAGR of 5.6% for Grade A+ assets.
• · The projected mark-to-market opportunity for PropShare Titania is 10.3% by FY2029.
• · The first Annual Meeting of Unitholders will be held on July 6, 2026 at 1300 Hrs IST via video conferencing.

09-06-2026

Emirates NBD Bank (P.J.S.C.) has launched an open offer to acquire up to 26% of the expanded voting share capital of RBL Bank Limited, consisting of 415,586,443 equity shares of ₹10 each, from public shareholders. As of June 9, 2026, no shares (0 equity shares, 0.00% of the offer size) have been tendered into the designated escrow demat account, indicating no initial uptake. The offers remain subject to document validation and SEBI (SAST) Regulations.

• · The open offer is governed by SEBI (SAST) Regulations, 2011.
• · Escrow demat account opened with Ventura Securities Limited (DP ID: IN303116, Client ID: 15744215, PAN: AABCT3335M).
• · Tendered shares are subject to validation and verification of complete documentation.
• · The number of shares tendered (0) differs from shares ultimately accepted, pending verification.

09-06-2026

Sarla Performance Fibers Limited has extinguished 40,00,000 equity shares (face value ₹1 each) bought back at ₹110 per share for a total consideration of ₹44,00,00,000 (₹44 Crore) via the tender offer route. Post extinguishment, the company's issued and paid-up capital reduced from 8,35,03,000 shares (₹8,35,03,000) to 7,95,03,000 shares (₹7,95,03,000). Promoter shareholding increased from 57.11% to 59.98%, while foreign investor shareholding jumped from 2.52% to 40.02%, reflecting a significant ownership shift.

• · The buyback was conducted via the tender offer route with a tendering period from May 21, 2026 to May 27, 2026.
• · All 40,00,000 extinguished shares were in dematerialized form; no shares were bought back in physical form.
• · The share extinguishment was effective June 5, 2026, as confirmed by NSDL and CDSL on June 5 and June 8, 2026, respectively.
• · Foreign investor holdings surged from 2.52% to 40.02% post-buyback, while public (including bodies corporate) holdings decreased from 38.64% to effectively 0% (not explicitly stated but implied by the post-buyback table).
• · Indian financial institutions/banks/mutual funds/government companies held 1.74% pre-buyback but are not listed in the post-buyback table, suggesting they tendered all their shares.